Please ensure Javascript is enabled for purposes of website accessibility

White House Claims Other Countries Are "Free-Riding" on U.S. Drug Development

By Brian Orelli, PhD - Feb 13, 2020 at 2:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's gotten worse over the last 15 years.

The problem isn't that U.S. drug prices are too high, it's that other countries are too low, concludes a new report from the Council of Economic Advisers, a White House task force. The group thinks other countries are "free-riding" on U.S. investment and innovation in drug development, a problem that it said has increased over the last 15 years.

In 2003, European countries were paying an average of 51% of U.S. prices, but by 2017 the average price was only 32% of the U.S. cost. "Many other developed nations with monopoly government insurance plans can push prices down below the value of the treatment as reflected by U.S. prices paid by private insurers in a free market," the report notes.

Medication on $100 bills

Image source: Getty Images

If countries paid prices relative to their gross domestic product (GDP) per capita, the report estimates that foreign countries would have paid $194 billion more in 2017, which would have raised global revenue for the "innovator firms" by 42%.

Canada, for example, has a GDP per capita that's 78% of the U.S., but paid 35% of U.S. prices for the top-selling drugs available in both countries. If it paid 78% of U.S. prices, Canada would have added $15 billion to the coffers of drug innovators.

The big question is what drug companies, such as Pfizer (PFE 0.78%), Bristol-Myers Squibb (BMY 0.40%) and Gilead Sciences (GILD -0.39%), would do with the windfall. They could pay it out to shareholders, but the task force thinks the money would result in an increase in innovation, which would lead to more competition that would ultimately lower prices for U.S. patients.

Unfortunately, the task force didn't offer up any solutions on how to get the "free-riding" countries to pay their fair share.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.13 (0.78%) $0.42
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$77.55 (0.40%) $0.31
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$64.76 (-0.39%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.